|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
101.95(B) |
Last
Volume: |
351,356 |
Avg
Vol: |
769,142 |
52
Week Range: |
$692.45 - $993.35 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
24,729 |
84,192 |
120,701 |
282,978 |
Total Sell Value |
$23,631,267 |
$76,701,012 |
$107,160,703 |
$220,505,683 |
Total People Sold |
7 |
13 |
15 |
17 |
Total Sell Transactions |
14 |
38 |
55 |
116 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Landry Robert E |
EVP Finance CFO |
|
2022-03-17 |
4 |
D |
$682.50 |
$195,195 |
D/D |
(286) |
28,956 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-03-17 |
4 |
OE |
$381.92 |
$139,401 |
D/D |
365 |
29,242 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-03-17 |
4 |
AS |
$686.00 |
$56,938 |
D/D |
(83) |
28,877 |
|
-14% |
|
Zoghbi Huda Y |
Director |
|
2022-03-16 |
4 |
AS |
$675.00 |
$1,350,000 |
D/D |
(2,000) |
1,082 |
|
-14% |
|
Zoghbi Huda Y |
Director |
|
2022-03-16 |
4 |
OE |
$391.92 |
$783,840 |
D/D |
2,000 |
3,082 |
|
- |
|
Tessier-Lavigne Marc |
Director |
|
2022-03-16 |
4 |
AS |
$675.00 |
$2,943,675 |
D/D |
(4,361) |
2,269 |
|
-14% |
|
Tessier-Lavigne Marc |
Director |
|
2022-03-16 |
4 |
OE |
$374.12 |
$1,631,537 |
D/D |
4,361 |
6,630 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-03-16 |
4 |
AS |
$677.00 |
$203,100 |
D/D |
(300) |
28,960 |
|
-14% |
|
Vagelos P Roy |
Director |
|
2022-03-14 |
4 |
D |
$655.29 |
$31,521,415 |
D/D |
(48,103) |
345,566 |
|
- |
|
Vagelos P Roy |
Director |
|
2022-03-14 |
4 |
OE |
$179.13 |
$13,434,750 |
D/D |
75,000 |
393,669 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2022-03-01 |
4 |
AS |
$615.39 |
$615,390 |
D/D |
(1,000) |
19,644 |
|
1% |
|
Mccourt Marion |
EVP Commercial |
|
2022-03-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
20,644 |
|
- |
|
Ryan Arthur F |
Director |
|
2022-03-01 |
4 |
AS |
$607.28 |
$61,837 |
D/D |
(100) |
22,382 |
|
1% |
|
Sing George L |
Director |
|
2022-02-28 |
4 |
S |
$614.00 |
$1,231,000 |
D/D |
(2,000) |
26,049 |
|
-1% |
|
Sing George L |
Director |
|
2022-02-25 |
4 |
S |
$621.00 |
$1,242,000 |
D/D |
(2,000) |
28,049 |
|
2% |
|
Brown Michael S |
Director |
|
2022-02-23 |
4 |
S |
$608.68 |
$304,340 |
I/I |
(500) |
7,162 |
|
2% |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-02-23 |
4 |
S |
$607.94 |
$4,163,489 |
D/D |
(6,781) |
30,578 |
|
2% |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-02-22 |
4 |
D |
$610.56 |
$20,282,193 |
D/D |
(33,219) |
37,359 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-02-22 |
4 |
OE |
$399.66 |
$15,986,400 |
D/D |
40,000 |
70,578 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2022-02-15 |
4 |
AS |
$622.09 |
$2,227,851 |
D/D |
(3,540) |
58,470 |
|
-4% |
|
Murphy Andrew J |
EVP Research |
|
2022-02-14 |
4 |
D |
$626.79 |
$4,049,063 |
D/D |
(6,460) |
62,010 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2022-02-14 |
4 |
OE |
$179.13 |
$1,791,300 |
D/D |
10,000 |
68,470 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2022-02-01 |
4 |
AS |
$607.46 |
$607,460 |
D/D |
(1,000) |
19,644 |
|
-7% |
|
Mccourt Marion |
EVP Commercial |
|
2022-02-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
20,644 |
|
- |
|
1366 Records found
|
|
Page 16 of 55 |
|
|